Skip to content
10-K

Annual Report

Damora Therapeutics, Inc. DMRA

0001193125-26-115922

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 17, 2026 60.3M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.36M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.16M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$6.73M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$18.62M
Cash And Equivalents FY 2025 · Dec 31, 2025 $257.62M
Cash And Equivalents FY 2025 · Dec 31, 2024 $14.18M
Stockholders Equity FY 2025 · Dec 31, 2025 $240.38M
Stockholders Equity FY 2025 · Dec 31, 2024 $15.83M
Stockholders Equity FY 2025 · Dec 31, 2023 $32.33M
Current Liabilities FY 2025 · Dec 31, 2025 $20.07M
Current Liabilities FY 2025 · Dec 31, 2024 $1.2M
Total Liabilities FY 2025 · Dec 31, 2025 $20.15M
Total Liabilities FY 2025 · Dec 31, 2024 $1.3M
Current Assets FY 2025 · Dec 31, 2025 $260.42M
Current Assets FY 2025 · Dec 31, 2024 $16.84M
Total Assets FY 2025 · Dec 31, 2025 $260.53M
Total Assets FY 2025 · Dec 31, 2024 $17.13M
Eps Diluted FY 2025 · Dec 31, 2025 $3.98
Eps Diluted FY 2025 · Dec 31, 2024 −$18.53
Eps Basic FY 2025 · Dec 31, 2025 $3.98
Eps Basic FY 2025 · Dec 31, 2024 −$18.53
Sga Expense FY 2025 · Dec 31, 2025 $9.69M
Sga Expense FY 2025 · Dec 31, 2024 $10.5M
Rd Expense FY 2025 · Dec 31, 2025 $26.88M
Rd Expense FY 2025 · Dec 31, 2024 $6.4M
Net Income FY 2025 · Dec 31, 2025 −$209.84M
Net Income FY 2025 · Dec 31, 2024 −$21.44M
Operating Income FY 2025 · Dec 31, 2025 −$210.87M
Operating Income FY 2025 · Dec 31, 2024 −$22.26M